Professor Loibl questions the necessity of aggressive ovarian suppression (GnRH analogs) for premenopausal patients with HER2+/HR+ metastatic breast cancer. Since HER2 is the dominant driver, less intensive endocrine therapy, such as tamoxifen, may be a reasonable maintenance strategy, especially when combined with a CDK4/6 inhibitor.

The innovation landscape for ER-positive metastatic breast cancer follows three parallel themes: 1) Developing superior endocrine agents like oral SERDs, 2) Advancing combination therapies with novel inhibitors (PI3K, mTOR, AKT), and 3) Creating new antibody-drug conjugates (ADCs) for patients who have become endocrine-resistant and would otherwise receive chemotherapy.

Hormone receptor-positive (HR+) HER2+ breast cancers often show lower rates of pathologic complete response (pCR) to pre-surgical therapy. This is due to their slower-growing biology, not treatment ineffectiveness. Clinicians should recognize this nuance and not assume a worse prognosis based on pCR alone in this subtype.

Positive data from both DESTINY-Breast09 (TDXD-based) and PATINA (CDK4/6i maintenance) create a new dilemma. With similar PFS outcomes, the first-line choice for metastatic HER2+/HR+ patients now hinges on toxicity profiles and patient preference rather than a single efficacy winner.

Even within recent major clinical trials like HER2CLIMB-05, less than half of eligible hormone receptor-positive patients received endocrine therapy. This highlights a critical and widespread gap in clinical practice, as this treatment adds significant benefit.

NGS testing is revealing that acquired HER2 kinase domain mutations, not amplifications, are an emerging resistance mechanism in ER+ lobular breast cancer. This creates a targetable population for HER2 TKIs like neratinib or tucatinib, offering a new line of targeted therapy.

Based on recent trial data, the optimal maintenance strategy for HER2+ metastatic breast cancer differs by subtype. The speaker suggests palbociclib for hormone receptor-positive patients and tucatinib for hormone receptor-negative patients, reflecting a personalized, data-driven treatment approach.

In addition to improving systemic progression-free survival, maintenance therapies with palbociclib (PATINA trial) and tucatinib (HER2CLIM-05 trial) both demonstrated a benefit in reducing central nervous system (CNS) progression, a critical secondary benefit for HER2+ patients.

The Avera trial’s design combined jiridestrant with everolimus to simultaneously target the primary estrogen-driven pathway and a known parallel resistance pathway (mTOR/PI3K/AKT). This created two blockades to prevent cancer cells from finding an escape route, showcasing an elegant trial strategy.